SGK1 inhibition in glia ameliorates pathologies and symptoms in Parkinson disease animal models by 유제욱 et al.
Article
SGK1 inhibition in glia ameliorates pathologies and
symptoms in Parkinson disease animal models
Oh-Chan Kwon1,2,3,† , Jae-Jin Song1,2,†, Yunseon Yang1,2,3,†, Seong-Hoon Kim1,2,3, Ji Young Kim1,2,3,
Min-Jong Seok1,2,3, Inhwa Hwang4, Je-Wook Yu4 , Jenisha Karmacharya5, Han-Joo Maeng5,
Jiyoung Kim6, Eek-hoon Jho6 , Seung Yeon Ko1,2,3, Hyeon Son1,2,3, Mi-Yoon Chang1,2,* & Sang-Hun Lee1,2,3,**
Abstract
Astrocytes and microglia are brain-resident glia that can establish
harmful inflammatory environments in disease contexts and thereby
contribute to the progression of neuronal loss in neurodegenerative
disorders. Correcting the diseased properties of glia is therefore an
appealing strategy for treating brain diseases. Previous studies have
shown that serum/ glucocorticoid related kinase 1 (SGK1) is upregu-
lated in the brains of patients with various neurodegenerative disor-
ders, suggesting its involvement in the pathogenesis of those
diseases. In this study, we show that inhibiting glial SGK1 corrects
the pro-inflammatory properties of glia by suppressing the intracel-
lular NFκB-, NLRP3-inflammasome-, and CGAS-STING-mediated
inflammatory pathways. Furthermore, SGK1 inhibition potentiated
glial activity to scavenge glutamate toxicity and prevented glial cell
senescence and mitochondrial damage, which have recently been
reported as critical pathologic features of and therapeutic targets in
Parkinson disease (PD) and Alzheimer disease (AD). Along with those
anti-inflammatory/neurotrophic functions, silencing and pharmaco-
logical inhibition of SGK1 protected midbrain dopamine neurons
from degeneration and cured pathologic synuclein alpha (SNCA)
aggregation and PD-associated behavioral deficits in multiple
in vitro and in vivo PD models. Collectively, these findings suggest
that SGK1 inhibition could be a useful strategy for treating PD and
other neurodegenerative disorders that share the common pathol-
ogy of glia-mediated neuroinflammation.
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Introduction
Parkinson disease (PD) is a common neurodegenerative disorder
characterized by the degeneration of dopamine (DA) neurons in the
substantia nigra (SN) of the midbrain and toxic intra-neuronal inclu-
sion of misfolded synuclein alpha (Lewy bodies and neurites). Stud-
ies have shown that PD’s pathologic features are caused by
mitochondrial damage/dysfunction, endoplasmic reticulum stress,
and defects in vesicular trafficking, synaptic recycling, and auto-
lysosomal pathways in midbrain DA (mDA) neurons (Nguyen et al,
2019). Along with those intra-neuronal dysfunctions, persistent
inflammation mediated primarily by neighboring glia commonly
underlies PD and other neurodegenerative disorders (Yan et al,
2014; Guzman-Martinez et al, 2019).
Astrocytes and microglia are brain-resident glial cells that typi-
cally play a homeostatic and neurotrophic role supporting neuronal
cell survival and functioning and maintaining brain homeostasis in
other ways (Horner & Palmer, 2003; Nedergaard et al, 2003; Molof-
sky et al, 2012). However, the naı̈ve homeostatic properties of glia
are compromised in disease contexts, and they instead establish
harmful inflammatory brain environments by secreting inflamma-
tory mediators (frequently annotated as M1 [microglia] and A1
[astrocyte] activation; Neumann et al, 2009; Liddelow et al, 2017a).
The idea of polarizing pathologic M1(A1)-type glia back into their
neurotrophic/homeostatic forms (M2 and A2 types) to treat
neurodegenerative diseases for which there are no disease-modify-
ing therapies has gained momentum (Hamby & Sofroniew, 2010).
A previous study demonstrated that nuclear receptor subfamily 4
group A member 2 (NR4A2, also known as NURR1), originally
known as a transcription factor specific for developing and adult
mDA neurons, can also be expressed in astrocytes/microglia in
response to toxic insults and that Nurr1-expressing glia protect
neighboring mDA neurons by prohibiting the synthesis and release
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of pro-inflammatory cytokines from glial cells (Saijo et al, 2009).
This Nurr1-mediated anti-inflammatory action in glia has been
manifested in various brain disease contexts (Loppi et al, 2018;
Popichak et al, 2018; Montarolo et al, 2019; Shao et al, 2019). Other
studies have shown that forkhead box A2 (FOXA2; also known as
HNF3B) is a potent cofactor that synergizes the anti-inflammatory
role of Nurr1 in glia (Oh et al, 2015; Song et al, 2018). Studying
intracellular anti-inflammatory pathways downstream of Nurr1 +
Foxa2 in glia could be valuable for identifying reliable therapeutic
targets to treat neurodegenerative disorders, including PD.
Serum/ glucocorticoid related kinase 1 (SGK1) is a gene first
identified as upregulated by serum and glucocorticoids in rat
mammary tumor cells (Firestone et al, 2003). SGK1 expression is
widely detected in the brain, and it is increased in pathologic condi-
tions such as Rett syndrome (Nuber et al, 2005), Alzheimer disease
(Chun et al, 2004; Lang et al, 2010; Zhang et al, 2018), multiple scle-
rosis (Wang et al, 2017), amyotrophic lateral sclerosis (Schoenebeck
et al, 2005), and neuropathic pain (Geranton et al, 2007; Peng et al,
2013). The level of SGK1 is relatively higher in the midbrain than in
other brain regions, and upregulation of SGK1 coincides with the
onset of DA neuron death in a model of PD (Iwata et al, 2004;
Stichel et al, 2005), collectively suggesting that SGK1 plays patho-
genic roles in PD and other neurodegenerative disorders. However,
SGK1 role in CNS is not clearly identified. In this study, we show
that Sgk1 is a molecule that is negatively regulated by Nurr1 (N)
and Foxa2 (F) in glial cells. We also show that glial inhibition of
SGK1 mediates the anti-inflammatory functions of N + F. In addi-
tion to its anti-inflammatory effects, SGK1 inhibition in glia potenti-
ates the neuroprotective functions of glia and prevents glial cell
senescence, which has recently been reported as a critical pathologic
feature of and therapeutic target in AD and PD (Bussian et al, 2018;
Chinta et al, 2018). Using multiple in vitro and in vivo PD models,
we show that silencing and pharmacological inhibition of SGK1 are
effective therapeutic tools for treating PD.
Results
SGK1 inhibition in glia suppresses NFκB-mediated
pro-inflammatory cytokine gene expression
We and other research groups have previously shown that the
midbrain factors N and F exert anti-inflammatory effects in glia by
inhibiting the transcription of pro-inflammatory cytokines (Saijo
et al, 2009; Oh et al, 2015; Song et al, 2018). In our microarray data
(accession no. GSE145489), one of the genes that N and F most
synergistically downregulated in glia cultured from mouse cortices
was Sgk1 (reduced 9.3-fold by N and F in combination; Fig 1A and
B). We further observed a similar reduction in SGK1 expression in
N + F-expressing astrocytes derived from a mouse ventral midbrain
(VM) in our RNA-sequencing data (RNA-seq; accession no.
GSE106216; Fig 1C), which we validated in VM-derived glial
cultures (GFAP+ astrocytes > 70%, IBA1+ microglia < 15%, expo-
sure to H2O2, 250 µM, 4 h) using qPCR analyses (Fig 1D). SGK1
inhibition attracted our interest because SGK1 could regulate NFκB
signal, the central intracellular pathway responsible for inflamma-
tory cytokine transcription (Lawrence, 2009; Liu et al, 2017). Specif-
ically, SGK1 is suggested to phosphorylate IκB kinase subunit beta
(IKKB), which activates NFκB signaling by releasing NFκB from the
inhibitory IκB-NFκB complex(Lang & Voelkl, 2013). Indeed, Western
blot (WB) analyses showed that downregulating SGK1 proteins by
forcing the expression of N and F in cultured VM-derived glial cells
was followed by a decrease in phosphorylated (activated) IKKB and
IκB (Fig 1E). Consequently, compared to the mock-transduced
control glia, the higher proportion of the NFκB in N- and F-trans-
duced glia was inactively trapped in the complex associated with
IκB in cytosol (Fig 1F). The inactivation of NFκB signaling was
further manifested by decreased levels of phosphorylated (activated)
p65 (RELA: RELA proto-oncogene, NF-kB subunit), a major NFκB
component, and decreased levels of RELA (p65) proteins trans-local-
ized into the nucleus (Fig 1E). The N + F-mediated inactivation of
NFκB signals in glia was recovered by the forced expression of
SGK1 (Fig 1G), and the expression of pro-inflammatory cytokines
reduced by N + F treatment returned to levels similar to those in
the control glia (Fig 1H). NFκB activation induced by lipopolysac-
charide (LPS, 1 mM, 24 h), a toll-like receptor 4 ligand, greatly
subsided in cultured glial cells in the presence of a SGK1 inhibitor
(GSK-650394) (Fig 1I). As expected, SGK1 inhibition using treat-
ment with siRNA, sh-RNA, and specific inhibitors (EMD-638683,
GSK-650394) consistently downregulated the key pro-inflammatory
cytokines IL-1β, TNFα, IL-6, and iNOS (Fig 1J–M), whereas the
overexpression of SGK1 had the opposite effect (Fig 1N). These find-
ings collectively indicate that N + F-mediated anti-inflammatory
functions in glia are substantially attained by blocking SGK1 signal-
ing (Fig 1O), and thus, SGK1 inhibition could be used to treat
neurodegenerative disorders in which neuroinflammation is a
common underlying pathology.
SGK1 inhibition-mediated transcriptome changes are
associated with immune/inflammation reaction and glial
activation/polarization
The main purpose of this study was to test whether SGK1 inhibition
in glial cells could be used to develop a therapy for PD. Therefore,
glial cells were cultured from rodent VMs, which is primarily
affected in PD. VM-glial cultures of GFAP+ astrocytes (60–70% of
total cells) and Iba1+ microglia (5–15%, cf > 19.7  1.7% counted
in mouse adult midbrain) were used throughout this study unless
otherwise noted because astroglia and microglia interact closely to
prevent or exacerbate disease pathogenesis (Jha et al, 2019), and
thus, the consequences of their interactions in mixed glia, not the
isolated individual actions of astrocytes and microglia, are the target
in developing therapeutic interventions for brain disease. To gain
further insight into how SGK1 inhibition affects glial functions, we
performed an RNA-seq analysis (GSE145490) in primary VM-derived
glial cultures with and without the SGK1 inhibitor GSK-650394.
Consistent with the SGK1 inhibition effects shown in Fig 1, genes
downregulated by the SGK1 inhibitor (FPKM > 1, > 2.6 fold change
[FC]) were found in the gene ontologies associated with “inflamma-
tory reaction” and the “NFκB pathway” (highlighted in red in Fig 2A
and B). Actually, 7 of the top 10 ontologies of the downregulated
genes were related to inflammatory/immune reactions. The enrich-
ment of differentially regulated genes (DEGs) in inflammatory/im-
mune pathways was further confirmed by gene set enrichment
analyses (Fig 2C). Furthermore, immune/inflammatory genes were
the most significantly downregulated by the inhibitor treatment
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(Fig 2D and E). Using a 2-FC cutoff and 1% false discovery rate
(FDR), 726 genes downregulated by the SGK1 inhibitor were also
downregulated by N + F, and the overlapping genes were also found
in the gene categories of immune/inflammation and the NFκB path-
way (Appendix Fig S1A, C, E), further confirming that N + F inhibi-
tion of glial inflammation via the NFκB pathway is mediated by
inhibiting SGK1 intracellular signals in glial cells.
In the RNA-seq data, the expression of all the M1-specific markers
reported (Ka et al, 2014) was downregulated by treatment with the
SGK1 inhibitor. The expression of the M2 markers Il10, Ccl22, Egf,
Fizz1, and Il2ra was upregulated, while five of them were downregu-
lated (Fig 2F), indicating SGK1 inhibition establishes its own microglial
transcriptome signature mainly by inhibiting M1 marker transcription.
Out of 13 pan-reactive astrocyte markers (Liddelow et al, 2017b), 10
were upregulated in the glial cultures treated with the inhibitor.
However, there was no clear A1–A2 trend in the astrocyte-specific
marker expression patterns, indicating that SGK1 inhibition induces a
distinct glial reactivity profile, as also shown in other recent studies
(Marschallinger et al, 2020; Smith et al, 2020; Zhou et al, 2020).
NLRP3-inflammasome- and CGAS-STING-mediated inflammatory
pathways in glia are suppressed by SGK1 inhibition
Downregulated inflammatory genes in the RNA-seq data included the
key components of the NLR family pyrin domain containing 3
(NLRP3) inflammasome signal (Fig 3A), which is required for the acti-
vation of IL1B and IL18 and thus regarded as the archetypical molecu-
lar driver of inflammatory response (reviewed in ref. Afonina et al,
2017). The decreased mRNA expression of Nlrp3, PYD and CARD
domain containing (Pycard, also known as Asc) apoptosis-associated
speck-like protein containing a caspase recruitment domain (ASC),
and procaspase-1 was validated in independent cultures treated with
the SGK1 inhibitor, sh-Sgk1, and si-Sgk1 (Fig 3B), indicating that
SGK1 signals are involved in NRLP3 inflammasome activation in glial
cells. Note that the transcriptional control of NLRP3 inflammasome
components is considered rate limiting in the activation of the
inflammasome (Huai et al, 2014; Ising et al, 2019). To determine
whether SGK1 inhibition could indeed prevent the activation of the
glial NRLP3 inflammasome pathway, VM-derived glial cells cultured
in the presence or absence of the SGK1 inhibitor (for 4 days) were
primed with LPS (0.25 µg/ml, 3 h), and then followed by ATP treat-
ment (2.5 mM, 30 min). In the control cultures, the sequential LPS-
ATP treatment robustly induced the activation of caspase1 and the
secretion of IL1B, as determined by the detection of active caspase1
(p10) and mature/activated IL1B protein levels in the control cell
culture supernatants (Fig 3C). By contrast, activated and secreted
caspase1 and IL1B were markedly decreased to almost undetectable
levels in the cultures treated with the SGK1 inhibitor. The reduced
activation of the NLRP3 inflammasome through SGK1 inhibition was
further confirmed by the ELISA detection of IL1B in the culture
medium (Fig 3D). The activation of the NRLP3-inflammasome has
lately been reported as a central pathogenic contributor to neurode-
generative diseases (Voet et al, 2019), including AD (Heneka et al,
2013; Venegas et al, 2017; Ising et al, 2019) and PD (Mao et al, 2017;
Lee et al, 2018), further indicating that SGK1 inhibition in glia could
be a therapeutic intervention for those disorders.
We also observed that the inflammatory genes downregulated
in the glial cultures treated with the SGK1 inhibitor included
components of the cyclic GMP-AMP synthase (CGAS)-stimulator of
interferon response cGAMP interactor 1 genes (STING) pathway
(Fig 3E and F), which has recently been identified as another criti-
cal pathogenic contributor to PD caused by Parkin and PINK1
mutations (Sliter et al, 2018). To assess the regulation of CGAS-
STING signaling by glial SGK1 inhibition, VM-glia were treated
with H2O2 (250 µM) and LPS (1 mM), chemicals reported to acti-
vate that pathway (Gehrke et al, 2013; Wang et al, 2019). In this
treatment condition, the activation of the STING pathway was
evidenced by increased levels of CGAS, STING, phospho-TBK1,
and phospho-IRF3 proteins (Fig 3G). Treatment with the SGK1
inhibitor significantly blunted the increased activation of those
CGAS-STING signal molecules in the cultured VM-glia (Fig 3G)
and drastically decreased the expression of Ifnb1 mRNA, a final
product of the CGAS-STING pathway (Fig 3H). Collectively, these
findings show that SGK1 inhibition in glia strongly potentiates
anti-inflammatory functions by suppressing the NFκB, NLRP3-in-
flammasome, and CGAS-STING signal pathways.
◀ Figure 1. SGK1 inhibition is the key mediator for Nurr1 + Foxa2-induced anti-inflammatory function in glial cells.
A–D Nurr1 (N) and Foxa2 (F) synergistically downregulate SGK1 expression in cultured glia. (A) Up- and downregulated genes in the microarray data for the cultured
glia transduced with N + F (vs. mock-transduced control). Sgk1 is marked with an arrow in the top downregulated genes. (B–D) Effect of N and F on SGK1
expression in glial cells shown in the microarray (B), RNA-seq (C), and RT–PCR (D) analyses. Data in (B and C) represent values of fold change (FC) or read count
(RC) with color intensities. n = 3. One-way ANOVA. Data are represented as mean  SEM. Significantly different at P = 0.0493*, 0.0092**, 0.0009***.
E–I Downregulation of SGK1 is responsible for N + F function to inhibit NFκB-mediated pro-inflammatory cytokine expression. (E) WB analysis exhibiting N + F-
induced inhibition of NFκB intracellular signaling in cultured VM-glia. The N + F-mediated downregulation of NFκB signaling is attained by inhibiting IκB
phosphorylation (E) and thus blocking the release of NFκB from the NFκB-IκB inhibitory complex (F). Data are represented as mean  SEM. n = 3 independent
experiments; one-way ANOVA with Tukey-analysis. P = 0.015#, 0.002##, 1.33E-12### (sgk1), 0.036#, 0.00004## (p-IKKB). 0.00007### (p-IkBα). 0.005#, 2.11E-09###
(p-p65). 1.93E-06### (p65 level in nucleus) in graph E. P = 6.44E-09*, 0.00004**, 4.45E-10*** in graph F. (G and H) N + F-mediated downregulation of NFκB
signaling (phosphorylation of p65, p-p65, G) and pro-inflammatory cytokine expression (IL-1β, TNFα, H) were alleviated by forced SGK1 expression in the VM-glial
cultures. Data are represented as mean  SEM. n = 3 independent cultures; two-way ANOVA with Bonferroni post hoc analysis. Significantly different at
P = 0.014#, 0.009*, 0.009**, 0.003+ (p-p65) in graph G and P = 1.79E-06*, 0.0003**, 0.004***, 0.0068#, 0.0392##, 0.0027### in graph H. (I) SGK1 inhibition blocks
glial NFκB signaling. Data are represented as mean  SEM. n = 4–6. One-way ANOVA. Significantly different at P = 0.002*, 0.00004**, 0.00001#, 3.01E-10##,
3.78E-06+, 1.59E-07++ in graph I.
J–N Glial pro-inflammatory cytokine expression regulated by SGK1 inhibition (J–M) and overexpression (N). Data are represented as mean  SEM. n = 3 independent
cultures; unpaired Student’s t-test. Significantly different at P = 0.0041*, 0.0010#, 0.0010+, 0.0067## in graph J and P = 0.0002*, 0.0345#, 0.0023+, 0.0012**,
0.0001## in graph K and P = 0.0367*, 0.0042+, 0.0003** in graph L and P = 0.0001*, 0.0009#, 0.0002+, 0.0082** in graph M and P = 0.0367*, 0.0059#, 0.0005**,
0.0006## in graph N.
O Schematic summary to show how SGK1 inhibition mediates the N + F-induced anti-inflammatory action in glia.
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SGK1 inhibition in glia upregulates glutamate clearance capacity
NFκB signaling activated in astrocytes has been shown to suppress
the expression of the glutamate transporter SLC1A2 (solute carrier
family 1 member 2; also known as EAAT2, GLT-1; Fine et al, 1996; Su
et al, 2003; Boycott et al, 2008; Jiang et al, 2019), the protein that
reduces glutamate toxicity by clearing extracellular glutamate and
thus protect neuronal cells from excitatory toxicity (Hansson et al,
2000). Consistently, along with the downregulated NFκB signaling in
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expression increase of the glutamate transporters Slc1a3 (solute
carrier family 1 member 3; also known as, GLAST, EAAT1) and Slc1a2
was seen in the RNA-seq data (GSE145490) by the SGK1 inhibitor
treatment (Appendix Fig S2A). The glutamate transporter expression
was further validated in independent cultures treated with the SGK1
inhibitors (Appendix Fig S2B). In addition, we found that SGK1 inhi-
bitor treatment significantly increased glutamate uptake activity in
cultured VM-glia (Appendix Fig S2C). It is noted that astrocytic GLT-1
(SLC1A2) deficiency caused mDA neuron death and PD symptoms
(Zhang et al, 2020), while increased GLT-1 expression has also been
shown to have beneficial and therapeutic effects (Kobayashi et al,
2018). Thus, these findings collectively indicate that SGK1 inhibition
enhances therapeutic capacity of glia via upregulation of glutamate
clearance as well as the anti-inflammatory activities.
Mitochondrial damage in glia is blunted by treatment with the
SGK1 inhibitor
Mitochondrial defects and dysfunction are the leading cause of
neurodegeneration (reviewed in ref. Johri & Beal, 2012; Lezi &
Swerdlow, 2012). Neurons are the central cell type to be studied for
the link between mitochondrial pathology and neurodegeneration in
PD and other disorders. The importance of mitochondrial biology in
glia has recently come into the spotlight (reviewed in ref. McAvoy &
Kawamata, 2019) especially because of reports demonstrating the
role of healthy mitochondria from astrocytes in rescuing neurons
from injury (Hayakawa et al, 2016) and demonstrating the patho-
logic contribution of damaged and fragmented mitochondria in glia
to M1(A1) polarization and thus the propagation of inflammatory
neurodegeneration (Joshi et al, 2019). The NLRP3-inflammasome
and CGAS-STING pathways, which were blocked by SGK1 inhibition
in glial cells (Fig 3), are closely linked to mitochondrial damage and
dysfunction (Sorbara & Girardin, 2011; Heid et al, 2013; Liu et al,
2016; Maekawa et al, 2019). In addition, the upregulated expression
of PGC1α, the master regulator for mitochondrial biogenesis (Wu
et al, 1999; Finck & Kelly, 2006), was detected in the RNA-seq data
from glia treated with the SGK1 inhibitor (Fig 4A) and confirmed
using qPCR (Fig 4B) and WB analyses (Fig 4C) in cultures treated
with GSK-650394 or EMD-638683, indicating that SGK1 inhibition
could affect mitochondrial functioning/metabolism in glia. As antici-
pated, the MitoTimer assay (Ferree et al, 2013; Hernandez et al,
2013) showed that the ratio of healthy or newly synthesized mito-
chondria (green fluorescence) to damaged or aged mitochondria
(red) was greater in glia treated with the SGK1 inhibitor than in
control glia (Fig 4D). Treating cultured VM-glia with H2O2 + CCCP
(mitochondrial toxin) increased the reactive oxygen species (ROS)
in the mitochondria (MitoSox) (Fig 4E) and reduced the mitochon-
drial membrane potential (JC-1) (Fig 4F). The toxin-induced mito-
chondrial damage in glia was significantly reduced in the presence
of the SGK1 inhibitor GSK-650394 (Fig 4E and F). Along with the
increased number of healthy mitochondria and reduced mitochon-
drial stress, intracellular levels of ATP, an indicator of mitochondrial
function (oxidative phosphorylation), increased in the glia treated
with GSK-650394 in a dose-dependent manner (Fig 4G). These find-
ings suggest that SGK1 inhibition improves glial mitochondrial
health and function, which could contribute to the neuroprotective
functions of glia (Hayakawa et al, 2016) and prevent glia-mediated
propagation of disease pathology (Joshi et al, 2019).
Effects of SGK1 inhibition on glial cell senescence
Recent studies have shown that cellular senescence in glia is
another key pathologic feature of neurodegenerative disorders, and
thus, clearing or preventing senescent glial cells has been suggested
as a therapeutic avenue for PD (Chinta et al, 2018) and AD (Bhat
et al, 2012; Bussian et al, 2018; Zhang et al, 2019). In the same
context, it has been acknowledged that astrocytic oxidative stress, a
leading cause of cell senescence, contributes to PD pathogenesis (re-
viewed in ref. Rizor et al, 2019). The following experimental
evidence from our and other studies strongly indicates that SGK1
inhibition could rescue glial cells from senescence and oxidative
stress. First, inflammation, shown in this study to be reduced by
SGK1 inhibition, is closely linked to increased ROS generation:
specifically, the pro-inflammatory cytokine TNFα binds to TNFR
and then produces intracellular ROS via NADPH oxidase 1/2 (re-
viewed in ref. Blaser et al, 2016). Second, our RNA-seq data show
that treating glia with an SGK1 inhibitor downregulated the pro-
oxidant Cyba, Ncf2, Recql4, Bax, and Fdxr and senescence-associ-
ated secretory phenotype (SASP) genes (Fig 4H). Third, SGK1 inhi-
bitor treatment repressed the formation of mitochondrial ROS
(MitoSox), a major source of intracellular ROS, in cultured glia
(Fig 4E). Therefore, we assessed whether oxidative stress and cellu-
lar senescence in glial cells could be alleviated by SGK1 inhibition.
As expected, oxidative stress, estimated using dihydrodichlorofluo-
rescein diacetate (DCF), a dye detecting cellular ROS, was greatly
reduced in H2O2-treated glial cultures by treatment with the SGK1
inhibitor (Fig 4I). We further observed that senescence-associated β-
galactosidase (SA-β-gal) activity, the hallmark senescence
biomarker, was promoted in glia exposed to H2O2 and significantly
rescued in the presence of the SGK1 inhibitor (Fig 4J). In addition,
in a paraquat-induced glial senescence model (Chinta et al, 2018), a
WB analysis showed that the herbicide-induced LMNB1 (Lamin B1)
◀ Figure 2. SGK1 inhibition-mediated transcriptome changes associated with immune/ inflammation reaction and microglial polarization.
In the RNA-seq data (GSE145490, normalized read count (RC) > 1, > 2.6-fold, 3,000 genes), genes downregulated in the VM-glia treated with the SGK1 inhibitor GSK-
650394 vs. the vehicle (DMSO)-treated control were analyzed.
A, B Top gene ontologies (GOs) and KEGG pathways of the genes downregulated in VM-glia by the SGK1 inhibitor treatment. The purple bar indicates the number of
genes under the designated GO term/KEGG pathway. The red bar indicates the p-value, and the negative log of the p-value (bottom) is plotted on the X-axis.
C Gene set enrichment analysis (GESA) for inflammatory and immune responses.
D Scatterplots for the differentially expressed genes (DEGs) highlighting the inflammatory/immune genes that are most significantly downregulated in the inhibitor-
treated cultures.
E Heatmap for selected inflammatory genes in the SGK1 inhibitor-treated and inhibitor-untreated glial cultures. Data represent the RC values (inside box) and log2
[SGK1 inhibitor-treated/control] (color intensity).
F Microglia and astrocyte reactivation-specific marker expressions in the RNA-seq data.
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loss, a senescence-associated biomarker (Freund et al, 2012), was
alleviated in glial cultures treated with the SGK1 inhibitor, and
levels of the pro-senescence proteins IL6, MMP3, and p16
(CDKN2A) also decreased (Fig 4K). Reduced secretion of IL6, a cyto-
kine of SASP, from cultured glia treated with the SGK1 inhibitor was
further demonstrated using ELISA (Fig 4L). Another key feature of
senescent cells is their inherent sensitivity to senolytic drugs. When
cultured glia were exposed to two different senolytic drugs that
target disparate molecular pathways, they demonstrated dose-
dependent loss of cell viability (Fig 4M). SGK1 inhibitor treatment
endowed the glia with significant resistance to the senolytic drugs.
These findings collectively suggest that SGK1 inhibition in PD brains
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SGK1 inhibition in glia ameliorates neuronal α-synuclein
aggregation in in vitro α-synucleinopathic models
Given the observed anti-inflammatory and neurotrophic effects of
glial SGK1 inhibition, we next examined whether SGK1 inhibition
could be a useful therapeutic tool in PD. Intra-neuronal misfolding
and the propagation of α-syn is a characteristic pathologic feature of
PD and a target of PD therapeutic interventions. It is acknowledged
that α-syn aggregation and propagation is promoted in a neuro-
inflammatory brain environment (reviewed in ref. Lema Tome et al,
2013). Specifically, recent studies have shown the ASC and caspase-
1 released from microglia trigger the neuronal accumulation of α-
syn aggregates (Wang et al, 2016; Gordon et al, 2018), and thus,
inhibition of the glial inflammasome pathway abolished α-synucle-
inopathy in a PD animal model (Gordon et al, 2018). Because
inflammation, especially the NLRP3-inflammasome pathway, was
strongly inhibited by SGK1 inhibition (Fig 3A–D), we postulated
that glial SGK1 inhibition might treat α-synucleinopathy and
performed experiments to test that possibility in several in vitro α-
synucleinopathy models. Because intra-neuronal SNCA (synuclein
alpha, α-synuclein) aggregations are formed by increasing SNCA
expression (Singleton et al, 2003; Chart ier-Harlin et al, 2004;
Thakur et al, 2017), we prepared mDA neuronal cultures that over-
expressed human SNCA and co-cultured them with VM-glia
(schematized in Fig 5A). To facilitate SNCA aggregate formation,
the co-cultures were treated with -SNCA preformed fibrils (PFFs),
which act as seeds for intracellular SNCA aggregation in neuronal
cells (Luk et al, 2009; Volpicelli-Daley et al, 2014). In this combined
SNCA overexpression + PFF treatment condition, SNCA aggregates
were readily formed and detected by immunoblot for SNCA and
immunocytochemical analyses against phosphorylated SNCA at
serine 129 (p129-SNCA) (Appendix Fig S3), which is associated
with toxic SNCA fibril formation (Anderson et al, 2006). Treating
the co-cultures with the SGK1 inhibitor GSK-650394 decreased the
level of SNCA oligomers and monomers in a WB analysis (Fig 5B)
and the p129-SNCA+ cell counts (Fig 5C). However, the SGK1 inhi-
bitor treatment effect was not manifested in primary neuron cultures
without glial cells (Appendix Fig S4), suggesting that the SGK1 inhi-
bitor effect to reduce α-synuclein pathology in the neuron + glia co-
cultures was mediated by the inhibitor action on the glia. Synucle-
iopathy spreads mainly by neuron-to-neuron transfer of SNCA prop-
agation (Luk et al, 2012). To further assess the effect of the SGK1
inhibitor on cell–cell SNCA transfer and aggregation, we used a
bimolecular fluorescence complementation (Bi-FC) system (Bae
et al, 2014), in which fluorescence emanates from the dimerization
or oligomerization between SNCA fused to the amino (N) terminus
(V1S) and that fused to the carboxy (C) terminus (SV2) fragment of
Venus, a variant of yellow fluorescence protein (Fig 5D). Primary
cultured VM-derived neural stem/precursor cells (NSCs) were indi-
vidually transduced with the V1S and SV2 constructs and differenti-
ated into neurons. Neither the neuronal cells expressing V1S nor
those expressing SV2 produced Bi-FC fluorescence (data not
shown). When the neuronal cells were co-cultured, however, fluo-
rescence was visualized by the Bi-FC system (Fig 5E), validating the
specificity of this model for assessing SNCA aggregation mediated
by cell–cell SNCA transmission. As anticipated, the number of Bi-FC
fluorescence puncta decreased greatly in the cultures treated with
the SGK1 inhibitor GSK-650394 (Fig 5E).
Next, to test the effect of glial SGK1 knockdown on neuronal
SNCA pathology, VM-glia were transduced with sh-SGK1 (or sh-
control for the control), and medium was conditioned in the sh-
SGK1-glia (sh-Cont-glia). The conditioned medium (CM) was
administered to primary mDA neuron cultures (schematized in Fig 5
F). After 8–10 days of SNCA PFF treatment, the monomer and
oligomer forms of SNCA were significantly lower in the mDA
neurons treated with the sh-SGK1 glia-derived CM (sh-SGK1-GCM)
vs. sh-cont-GCM, and the levels of nitrated SNCA, a pathologically
modified SNCA (He et al, 2019), had decreased (Fig 5G). Further-
more, p129-SNCA immunoreactivity (% p129-SNCA + out of total
TuJ1 + neurons) was significantly reduced by the administration of
sh-SGK1-GCM (Fig 5H).
In addition to the NLRP3-mediated inflammatory environment,
intra-neuronal oxidative and mitochondrial stresses are other prime
causes of pathologic SNCA aggregation (Esteves et al, 2009; Li et al,
2011; Scudamore & Ciossek, 2018). Mitochondrial damage causes
increased ROS through defective mitochondrial anti-oxidant func-
tions and increased Ca2+/calpain-mediated cleavage of SNCA
through defective mitochondrial Ca2+ buffering capacity, which ulti-
mately results in oxidized/nitrated and truncated SNCA, respec-
tively, which are prone to pathological aggregation (reviewed in ref.
Esteves et al, 2011). Consistent with the observed glial neurotrophic
and anti-inflammatory functions potentiated by SGK1 inhibition,
intra-neuronal mitochondrial and oxidative stresses, estimated by
MitoTimer, MitoSox, and DCF-staining, were greatly relieved in the
◀ Figure 3. Glial NLRP3-inflammasome and CGAS-STING inflammatory pathways downregulated by SGK1 inhibition in VM-glial cultures.
A, B mRNA expression of the NLRP3-inflammasome components Nlrp3, Pycard (Asc), and Caspase1. Decreased expression of the components shown in the RNA-seq (A)
was confirmed using qPCR analyses in other independent VM-glial cultures treated with the inhibitor (GSK-650394) and sh-Sgk1 and si-Sgk1 (vs. DMSO, sh-control,
and si-control, respectively) (B). n = 3; Student’s t-test. Data are expressed as mean  SEM. Significantly different at P = 0.0018*, 0.0405**, 0.0039***, 0.0002#,
0.0033##, 0.0099###, 0.0001####, 0.0056+, 0.0398++, 0.0067+++ in graph B.
C Immunoblot analysis to assess NLRP3 inflammasome activation. To activate the inflammasome pathway, VM-derived glial cells were treated with LPS (0.25 µg/ml,
3 h) and then ATP (2.5 mM, 30 min) in the presence or absence of the SGK1 inhibitor GSK-650394. Two days later, intracellular and released levels of pro- and
activated caspase-1 and IL-1β proteins were determined in the culture media and cell lysates, respectively.
D Released level of IL-1β (activated) was further quantified using ELISA. n = 3; ANOVA. Significantly different at p = 0.0002#, 0.0012*, 0.0004** in graph D.
E, F Expression of CGAS-STING pathway genes in the RNA-seq data. The graph represents log2 RC ratios of [GSK-650394-treated/DMSO-treated control]. The molecules
downregulated by the SGK1 inhibitor are marked with arrows in the CGAS-STING signal pathway schematized in F.
G WB analysis demonstrating suppression of CGAS-STING signaling by the SGK1 inhibitor in VM-glial cultures. Representative blots are shown on the left. The levels
of the active forms of CGAS-STING signaling molecules are quantified from 5–10 independent blots (right). Data are represented as mean  SEM. One-way ANOVA.
Significantly different at p = 0.001#, 0.014* (CGAS), 0.00004#, 0.0002* (STING), 0.017#, 0.037* (pTBK1), 0.009#, 0.045* (pIRF3), 0.012#, 0.036* (pP65) in graph G.
H Expression of Ifnb mRNA, a final product of the CGAS-STING pathway, determined by real-time PCR analyses. Data are represented as mean  SEM. n = 3;
Student’s t-test. Significantly different at p = 0.0459#, 0.0305* in graph H.
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mDA neuronal cultures treated with GCM, and those effects in
reducing neuronal oxidative/mitochondrial stress were enhanced by
administering sh-SGK1-GCM (Appendix Fig S5A–C). Further
notably, the levels of reduced glutathione (GSH), a strong anti-
oxidant, in the neuronal cells increased by GCM treatment, and the
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shSGK1-GCM than sh-Cont-GCM (Appendix Fig S5D). These find-
ings suggest that SGK1 inhibition in VM-glia potentiates glial actions
that inhibit toxic SNCA aggregate formation at least in part by reliev-
ing intra-neuronal oxidative and mitochondrial stresses.
SGK1 inhibition in VM-glia protects mDA neurons from
toxic insults
Next, we assessed the effects of glial SGK1 inhibition on in vitro cell
survival and the resistance of mDA neurons, a neuronal type
primarily affected in PD, to toxic insults. To this end, mDA neurons
were co-cultured with glia (both derived from mouse VM) in which
SGK1 was down- or upregulated (schematized in ref. Fig 6A). Cell
death (TH+ cell counts) and neurite degeneration (TH+ fiber
lengths) induced by extended culturing or exposure to the ROS
producing agent H2O2 were greatly prevented in mDA neurons co-
cultured with sh-SGK1-treated glia compared with those co-cultured
with sh-control-treated glia (Fig 6B), whereas SGK1-overexpressing
glia accelerated the mDA neurodegeneration especially induced by
the toxin treatment (Fig 6C). Given that glia play their neuroprotec-
tive/pro-inflammatory roles by secreting neurotrophic/pro-in-
flammatory factors (reviewed in ref. Tang & Le, 2016; Du et al,
2017), the observed effects of SGK1 inhibition in glia are probably
mediated, at least in part, in a paracrine manner. To test that suppo-
sition, we conditioned the medium in glial cultures and added that
conditioned medium (GCM) to primary mDA neurons (Fig 6D).
Consistent with the neurotrophic nature of physiologic homeostatic
glia, the cell viability of mDA neurons was promoted by adding
GCM (sh-cont-GCM), and sh-Sgk1-GCM had stronger protective
effects (Fig 6E). By contrast, when CM was prepared from glia
pretreated with LPS and H2O2, treatment with the challenged GCM
(Cll-GCM, Cll-sh-cont-GCM) worsened cell viability estimated by
TuJ1+ neuron counting and CCK8 cell viability assay (Fig 6E), indi-
cating polarization of the glia into M1(A1)-type. The challenged
GCM-mediated cell toxicity was much alleviated in mDA neuron
cultures treated with GCM prepared from sh-Sgk1-transduced glia
(Cll-sh-sgk1-GCM) (Fig 6E). It is acknowledged that normal glia and
glia in the early stage of brain diseases (injuries) have neurotrophic
properties, whereas those in the late (chronic) stage are detrimental.
Thus, our findings indicate that SGK1 inhibition is a broadly appli-
cable therapy regardless of the stage of neurodegenerative disorders
(brain injuries) or the polarity of the glia because it can not only
potentiate the neurotrophic functions of glia at the early disease
stage, but also alleviate or correct the neurotoxic properties of glia
in chronic disease environments. By contrast, the therapeutic utility
of many drug candidates, such as those that simply target brain
inflammation or glial phagocytosis, depends on the stage of the
disease because inflammation and glial phagocytic activity are
neuroprotective at the acute stage but detrimental at the chronic
stage of CNS disorders.
Practically, pharmacologic inhibition is the most applicable ther-
apeutic intervention. Chemical compounds, however, cannot be
readily controlled to specifically act on glial cells without affecting
neuronal cells in the brain being treated. Accordingly, if neuronal
SGK1 inhibition has an opposite effect on neuronal cell viability
(Chen et al, 2012), therapeutic efficacy might be eliminated or
reduced in brains treated with a pharmacologic inhibitor. Indeed,
we readily detected endogenous expression of SGK1 in neuronal
cells (Appendix Fig S6A). To test the effect of SGK1 inhibition on
neuronal cells, we conducted experiments with the SGK1 inhibitor
in primary mDA neuronal cultures in which the glial population had
been eliminated by Ara-C treatment (Kaech & Banker, 2006).
Compared with the vehicle-treated control cultures, mDA neuron
viability and resistance to a toxic H2O2 stimulus in cultures treated
◀ Figure 4. SGK1 inhibition protects glia from mitochondrial damage and cell senescence.
A, B Ppargc1a (PGC1α) mRNA expression upregulated in VM-glia treated with the SGK1 inhibitors in the RNA-seq data (A) and qPCR analysis (B). Data are represented
as mean  SEM. n = 3; Student’s t-test. Significantly different at P = 0.0011#, 0.0499* in graph B.
C Immunoblot for PGC1α protein expression. Data are represented as mean  SEM. n = 3. Student’s t-test. Significantly different at P = 0.0077* in graph C.
D Mitochondrial biogenesis estimated by MitoTimer reporter gene expression in cultured VM-glia. Green fluorescence indicates newly synthesized mitochondria, and
red fluorescence indicates old or damaged mitochondria. MFIs were estimated in three independent cultures (> 5 randomly selected microscopic fields/culture).
Data are represented as mean  SEM. One-way ANOVA. Significantly different at P = 3.78E-08*, 0.00003** in graph D.
E Mitochondrial ROS levels estimated using the MitoSox red probe. Fluorescence intensity was measured using ImageJ, and ROS levels are presented as mean
fluorescent intensity (MFI). Mitochondrial damage was induced by treatment with the mitochondrial toxins CCCP (2 µM) + H2O2 (500 µM) for 4 h. MFIs were
estimated in three independent cultures (> 5 randomly selected microscopic fields/culture). Data are represented as mean  SEM. One-way ANOVA. Significantly
different at P = 0.0013*, 0.0273# in graph E.
F Mitochondrial membrane potential (JC-1). The red fluorescence (JC-1 Aggregate) indicates disrupted mitochondrial membrane potential, and green fluorescence
(JC-1 Monomer, insets) indicates intact potential. The inset images were taken from the same microscopic fields of the respective JC-1 aggregate images.
Mitochondrial damage was induced by treatment with the mitochondrial toxins CCCP (2 µM) + H2O2 (500 µM) for 4 h. MFIs were estimated in three independent
cultures (> 5 randomly selected microscopic fields/culture). Data are represented as mean  SEM. One-way ANOVA. Significantly different at P = 0.0006*, 0.0093#
in graph F.
G Intracellular levels of ATP, an indicator of mitochondrial oxidative phosphorylation. Data are expressed as mean  SEM. n = 3 cultures; one-way ANOVA.
Significantly different at P = 0.0009*, 0.00004**, 0.04913#, 0.0024+ in graph G.
H–M Glial cell senescence rescued by SGK1 inhibition. (H) Expression of genes associated with cell senescence in the RNA-seq data (VM-glia with vs. without GSK-
650394 treatment). (I) Intracellular ROS levels estimated by DCF-DA. Data are represented as mean  SEM. n = 3; one-way ANOVA. Significantly different at
P = 0.0074*, 0.012# in graph I. (J) Senescence-associated β-galactosidase (SA-β-gal) activity. Data are represented as mean  SEM. n = 3; one-way ANOVA.
Significantly different at P = 2.05E-06*, 0.0042#, 0.0006+ in graph J. (K) Immunoblots for proteins associated with cell senescence. Significantly different at
P = 0.008*, 0.001# (TNFA), 0.01*, 0.009# (HMGB1), 7.32E-10*, 1.23E-8# (IL6), 9.62E-11*, 1.01E-5# (MMP3), 0.001*, 5.72E-4# (LAMIN B) in graph K. (L) IL-6 levels
secreted from cultured VM-glia. The cytokine levels were estimated using ELISA of the media from the VM-glia with and without the SGK1 inhibitor. Data are
represented as mean  SEM. n = 3 cultures. One-way ANOVA. Significantly different at P = 0.0028*, 0.0062# in graph L. (M) Glial cell viability following treatment
with senolytic compounds (azithromycin, fisetin). Data are represented as mean  SEM. n = 3; Student’s t-test. Significantly different at P = 0.0073*, 0.0018**,
0.0286#, 0.0269##, 0.0045### in graph M.
Data information: Scale bar, 20 µm.
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with the SGK1 inhibitor were slightly but insignificantly greater
(Appendix Fig S6B), and the opposite effect was not observed in
numerous independent experiments. Thus, SGK1 inhibition in
neuronal cells is at least not harmful. Consistently, along with the
neurotrophic roles of glia promoted by SGK1 inhibition, treating
mixed mDA neuron-glia cultures with the SGK1 inhibitor always
promoted the survival and resistance of mDA neurons (Fig 6F).
Next, we evaluated the contribution of each cell type of glia (mi-
croglia and astrocyte) and their interaction to the glial neuroprotec-
tive effects potentiated by SGK1 inhibition. To this end, we isolated
astrocytes and microglia from the VM-glial cultures. CM was
prepared from the cultured astrocytes (ACM) and microglia (MCM)
and administered to cultured mDA neurons exposed to H2O2
(250 µM) (Appendix Fig S7A). Cell viability, estimated using the
CCK8 assay, MAP2+, and TH+ neuronal counts, was improved in
the cultures treated with either ACM or MCM, but ACM had a
greater neuroprotective effect than MCM (Appendix Fig S7B, D, F).
When astrocytes were pretreated with MCM and then CM was
prepared from the MCM-pretreated astrocytes (M-ACM), the M-
ACM treatment exerted a more potent neuroprotective effect than
that seen with ACM treatment (Appendix Fig S7B, D, F), indicating
that astrocytes positively interact with microglia in their neuro-
trophic functions. Expectedly, SGK1 knockdown (shSgk1 treatment)
in cultured astrocytes and microglia potentiated the paracrine neuro-
trophic effects of those glial cell types (comparisons of sk-ACM vs.
ACM and sk-MCM vs. MCM in Appendix Fig S7C, E, G). Further-
more, neuronal viability enhanced by treatments with skM-ACM
and skA-MCM was significantly greater than those of M-ACM and
A-MCM, respectively (Appendix Fig S7 C, E, G). These findings
suggest that SGK1 inhibition in astrocyte and microglia potentiated
paracrine neurotrophic effects not only from individual astrocytes
and microglia, but also from the interplay between those glial cell
types.
Therapeutic potential of pharmacologic inhibition of SGK1 in PD
mouse models
Based on our in vitro data, we next sought to determine whether the
pharmacologic inhibition of SGK1 could forestall the degeneration
of mDA neurons and associated behavioral deficits in PD. To that
end, we chose the MPTP mouse model of PD (Beal, 2001) using a
sub-chronic systemic approach (MPTP intraperitoneal (i.p.) injec-
tion of 30 mg/kg for five consecutive days). Beginning one week
after the initial MPTP injection series, the mice received i.p.
injections of the SGK1 inhibitor GSK-650394 (3 mg/kg) or DMSO
(vehicle control) once a day. Behavioral assessments were
performed every week by an independent experimenter blinded to
treatment condition (schematized in Fig 7A). During the post-MPTP
treatment period, the times required to accomplish the tasks in the
beam and pole tests gradually increased in the MPTP-treated mice.
The behavioral deficits were significantly alleviated in the mice
treated with the SGK1 inhibitor beginning 4 weeks after the start of
SGK1 treatment (5 weeks post-MPTP injection; Fig 7B and C).
Furthermore, hypo-locomotor activity in the MPTP-PD mice was
also significantly improved by treatment with the SGK1 inhibitor
(Fig 7D). Compared with untreated mice (4,920  469 cells, n = 6),
injection of MPTP led to a massive loss of mDA neurons: TH+ mDA
neurons in the SN of the PD mice were reduced to 1,500  164 cells
(n = 20) 6 weeks post-MPTP injection. Treatment with the SGK1
inhibitor GSK-650394 significantly reduced mDA neuronal loss in
the SN (2,570  225 cells, n = 27, P < 0.05) (Fig 7E and F). The
TH+ mDA neurons in the SNs of MPTP-treated mice had small cell
bodies with blunted and fragmented neurites (Fig 7E enlarged
images 1–2, G and H), indicating they were undergoing neurodegen-
eration. On the other hand, the mDA neurons in the SNs of MPTP-
PD mice treated with the SGK1 inhibitor looked much healthier,
with larger cell bodies and longer neurite outgrowths (Fig 7E
enlarged images 3–4, G and H). Consistently, nigrostriatal dopamin-
ergic innervation was also substantially protected by SGK1 inhibitor
administration, as shown by the TH+ fiber intensities in the striatum
(Fig 7I and J). High-performance liquid chromatography–tandem
mass spectrometry revealed that the SGK1 inhibitor compound was
readily detectable in the brains of the MPTP-treated mice 30 min
after administration (10.4  1.0 ng/g brain, n = 3), indicating that
the therapeutic effects might have been due to inhibitor action in
brain glia.
We further assessed the therapeutic potential of the SGK1 inhi-
bitor in another PD mouse model generated by injecting human
SNCA PFF into the SN of the midbrain, in combination with adeno-
associated virus (AAV)-mediated overexpression of human SNCA
(Fig 7K), which is regarded as an animal model that is relevant to
PD pathogenesis and disease progress (Thakur et al, 2017). Consis-
tent with the previous findings observed in the MPTP-PD mouse
model (Iwata et al, 2004; Stichel et al, 2005), SGK1 expression
increased in the SNCA-injected SN and the increased SGK1 expres-
sion was ubiquitously detected in neuron, astrocyte, and microglia
populations (Appendix Fig S8). Behavioral deficits, assessed by the
beam and pole tests, progressed slowly in the α-synucleinopathic
◀ Figure 5. SGK1 inhibition potentiates the ability of VM-glia to inhibit neuronal SNCA aggregation and propagation in vitro.
A Schematic of the experimental procedure in (B and C).
B Western blot analysis for detecting SNCA oligomers. Data are represented as mean  SEM. n = 4; one-way ANOVA. Significantly different at P = 2.5E-07*, 1.65E-
07**, 0.022#, 0.029##, 0.046+, 0.015++, 0.0136&, 0.0016&& in graph B.
C Immunocytochemical detection of p-129-SNCA, associated with SNCA aggregation. Data are represented as mean  SEM. n = 6. Significantly different at
P = 0.0363* in graph C.
D, E Bi-FC-based assessment of the inter-neuronal propagation and aggregation of SNCA. (D) Schematic of the experimental procedures with Bi-FC system. Bi-FC+
inclusions (puncta) were counted in (E). Data are represented as mean  SEM. n = 5. Significantly different at P = 0.0446* in graph E.
F–H Glial SGK1 knockdown effect on neuronal SNCA pathology. (F), Schematic of the experimental procedure in (G, H). VM-glial cultures were transduced with sh-Sgk1
(or sh-cont) lentivirus. Medium was condition in sh-Sgk1-glia (or sh-cont-glia), and the conditioned medium (CM) treatment effects on neuronal SNCA aggregation
were assessed by WB (G) and p-129-SNCA immunocytochemical (H) analyses. Data are represented as mean  SEM. n = 3. Significantly different at P = 0.00003*,
0.0003**, 0.0012***, 0.00004****, 0.0321# in graph G and P = 0.0052* in graph H.
Data information: Student’s t-test. Scale bar, 20 µm.
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Figure 6. SGK1 knockdown in VM-glia potentiates glial neuroprotective effects in VM-derived midbrain dopamine (mDA) neuron cultures.
A–C Co-culture experiments. (A) Schematic for the experimental procedure. Glia derived from mouse VM were transduced with sh-Sgk1 (B) or SGK1 (CMV-Sgk1, C), and
co-cultured with VM-derived mDA neurons. Seven days after co-culture, cells were exposed to H2O2 (500 µM, 3 h) or not (−), and then mDA neuron viability (TH+
cell counts) and neurite degeneration (TH+ fiber lengths) were estimated. Data are represented as mean  SEM; n = 4 culture coverslips. Student’s t-test.
Significantly different at P = 0.033*, 0.0412**, 7.44E-23#, 1.39E-23## in graph B and P = 0.0489*, 0.0366**, 0.0078## in graph C.
D, E Glial neurotrophic functions potentiated by SGK1 downregulation were mediated in a paracrine manner. VM-glia transduced with sh-Sgk1 (or sh-cont as a control)
were challenged with H2O2 + LPS for 3 h or not. Glial conditioned medium (GCM) was prepared in each glial culture condition and administered to mDA neurons
primarily cultured from mouse VM (D). (E) Cell viability of the neuronal cells was estimated using CCK8 assays and TuJ1+ cell counts. Data are represented as
mean  SEM. n = 3 cultures; one-way ANOVA. Significantly different at P = 0.0002*, 3.29E-08**, 0.0003***, 3.66E-06#, 0.0029## (TuJ1+ cell counting), 0.0127+,
5.98E-06++, 0.0002+++, 0.0005&, 0.0078&& (CCK8 assays) in graph E.
F Effect of the SGK1 inhibitor treatment in the mixed mDA neuron + VM-glia co-cultures. Data are represented as mean  SEM. n = 3. Student’s t-test. Significantly
different at P = 0.0068*, 0.0368**, 0.0249#, 1.48E-27## in graph F.
Data information: Scale bar, 20 µm.
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PD mice. SGK1 inhibitor treatment significantly alleviated the
progress of the motor symptoms from 10 to 12 weeks (Fig 7L–N).
As previously described (Thakur et al, 2017), there is substantial
immunoreactivity for p129-SNCA in the SNs of mice injected with
the combined SNCA PFF + SNCA-AAV2, indicative of pathologic
SNCA aggregation. In the SNs of SNCA-PD mice treated with the
inhibitor GSK-650394, p129-SNCA immunoreactivity was signifi-
cantly reduced, especially in TH+ DA neurons (Fig 7O and P). Along
with the reduction in SNCA pathology, the degeneration of SN DA
neurons and axons (Fig 7O, Q–S) and loss of striatum TH+ fiber
intensities (Fig 7T and U) was significantly blunted in the animals
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SGK1 silencing using intra-SN injection of sh-SGK1 AAV9 is
another potential therapeutic tool for PD
Our final experiment tested whether silencing SGK1 using sh-RNA
delivery could be an effective therapeutic tool for PD. Before testing
the therapeutic effect in a PD mouse model, we examined the effi-
ciency of gene delivery using the AAV vector, which has been
suggested as a desirable therapeutic vector for CNS disorders (re-
viewed in ref. Hudry & Vandenberghe, 2019). AAV serotype 2
(AAV2), the most well characterized and frequently used in clinical
trials, has strong neurotropism without transgene expression in glial
cells (McCown, 2011; Oh et al, 2015), which excluded it from this
study because we wanted to deliver genes efficiently to glial cells. We
tested AAV9-mediated gene delivery because it was also suggested as
a compelling candidate for gene therapy in CNS disorders (Pattali
et al, 2019). We carried out stereotaxic injection of AAV9 carrying the
reporter green fluorescent protein (GFP) gene under the control of the
universal CMV promoter (GFP-AAV9) into the SN. The GFP exogene
expression was detected to cover whole midbrain regions and was
readily detected in astrocytes and microglia: Of the GFP+ cells, GFAP+
astrocytes accounted for 40.1  6.8%, Iba1+ microglia for
19.8  4.0%, and NeuN+ neurons for 34.3  5.5% (Fig 8A and B).
Given that efficient gene transfer to glial cells, we constructed AAV9
expressing sh-SGK1 to test its therapeutic effects (Fig 8C). SGK1
mRNA expression was efficiently downregulated in SNCA model PD
mice by intra-SN injection with sh-Sgk1-AAV9 (Fig 8D). Compared to
the sh-control-treated mice, immunohistochemical analysis against
SGK1 revealed 50, 60, and 45% reduction in SGK1-immunoreactive
cells in the neuron, astrocyte, and microglial populations of the SN
treated with sh-Sgk1-AAV9, respectively (Fig 8E). In addition to
preventing SNCA pathology (% p129-SNCA+ cells), mDA neuron
degeneration in the SN (Fig 8I–M) and loss of TH+ and DA transporter
(DAT)+ fiber intensities in the striatum (Fig 8N and O), intra-SN injec-
tion of sh-Sgk1-AAV9 ameliorated behavioral deficits in SNCA model
PD mice (Fig 8F–H).
Suppression of inflammation and cell senescence in the SN of PD
mice underlies the therapeutic effects attained by SGK1 inhibition
Compared with the vehicle-treated control PD mice, Iba1+ microglia
accumulated less abundantly in the SN and neighboring areas of the
GSK-650394-treated SNCA-PD mice (Fig 9A and B). In morphomet-
ric measurements, inflated (hypertrophic) microglia, a characteristic
of inflammatory reactive microglia, were much ameliorated in the
SNs of mice treated with the SGK1 inhibitor (see Insets in Fig 9A
and H), with a significant reduction in microglial soma sizes (Fig 9
C). Furthermore, the expression of the pro-inflammatory M1 marker
CD16/32 was localized in the lower proportion of microglia in the
SNs of mice treated with the inhibitor (Fig 9D and E). In accord with
the in vitro findings shown in Figs 1J–M and 2D–E, mRNA expres-
sion of the pro-inflammatory cytokines (Il1b, Tnfa) and key
inflammasome components (Nlrp3, Asc, Casp1) was significantly
lowered in the SNs of MPTP- and SNCA-PD model mice by adminis-
tering the SGK1 inhibitor (Fig 9F and G). The key NLRP3-inflamma-
some component ASC was barely detected in un-lesioned mice (data
not shown and (Gordon et al, 2018)), whereas ASC immunoreactiv-
ity was abundantly detected and localized in hypertrophic Iba1+
microglia in the SN area of control SNCA-PD mice (Fig 9H). Consis-
tent with the suppression of NLRP3 inflammasome activation with
glial SGK1 inhibition (Fig 3A–D), ASC immunoreactivity was greatly
reduced in the animals treated with the SGK1 inhibitor (Fig 9H–J).
SA-β-Gal activity was detectable in the midbrains 12 weeks after
SNCA-PFF + AAV injection (but not in the control and MPTP-PD
mice). Consistent with the in vitro observation that glial cell senes-
cence was reduced by SGK1 inhibition (Fig 4H–M), SA-β-gal staining
intensity in the mouse midbrain was markedly lowered by inhibitor
administration (Fig 9K and L). Next, to determine the cell type iden-
tity of the senescent cells, we attempted to use co-immunofluores-
cent staining for cell senescence markers (p16, TBP) with neuron-
or glial-specific markers, but we failed to get specific and positive
staining for the senescence markers. Thus, although the cell type
undergoing changes in cell senescence in the PD model remains to
be identified, our findings collectively suggest that SGK1 inhibition
could be used to treat PD by suppressing the glial activation of
inflammation, especially the NLRP3-inflammasome, and cellular
senescence (Appendix Fig S9).
Discussion
For decades, neuronal cells have been the central cell type
targeted for drug development in CNS disorders. However,
◀ Figure 7. Therapeutic effects of SGK1 inhibitor treatment in PD mouse models.
A–J Effect of treatment with the SGK1 inhibitor GSK-650394 in the MPTP-PD mouse model. (A) Overview of the experimental procedure. (B–D) Behaviors of MPTP-PD
mice assessed by pole (B), beam (C) at 3–6 weeks post-MPTP injection, and locomotor activity (total distance & average speed, D) tests at 6 weeks post-MPTP
injection. n = 20 GSK-650394-treated MPTP-PD mice, 14 vehicle-treated MPTP-PD mice, and 8 MPTP-untreated non-PD mice. Data are represented as
mean  SEM. Significantly different at P = 0.0012#, 0.0001*, 3.09E-08##, 8.21E-08** in graph B and P = 0.0009#, 0.0035*, 1.03E-06##, 0.00003** in graph C and
P = 0.0001*, 0.0284**, 0.0101# (total distance), 1.49E-08*, 0.0005**, 0.0001# (average speed) in graph D. Histologic assessment of the number of TH+ mDA
neurons (E, F), neurite lengths (E, G), and cell body sizes (E, H) of the mDA neurons in the SN and TH+ fiber intensities in the striatum (I, J). Shown in (E and I) are
the representative images for TH+ DA neurons in the SN and TH-immunoreactivity in the striatum, respectively. TH+ DA neurons in boxed areas of (E) are enlarged
in right. Data are represented as mean  SEM. n = 3–4 mice per group. Significantly different at P = 7.09E-09#, 0.0001##, 0.0162* in graph F and P = 5.09E-09#,
5.10E-09##, 6.66E-09* in graph G and P = 4.89E-08#, 0.0001##, 0.0152* in graph H and 5.10E-09#, 0.0128##, 0.0001* in graph J.
K–U Therapeutic effects of GSK-650394 in SNCA-PD model mice. Behaviors (L–N) and mDA neuron degeneration in the SN (O–U) of the SNCA-PD mice were assessed at
6–12 (L, M) and 12 weeks post-SNCA injection before (N) and after sacrifice (O–U). Significantly different at P = 0.008#, 0.021*, 0.00001##, 0.0009** in graph L and
P = 0.00002#, 0.0344*, 0.0005##, 0.0067** in graph M and P = 0.0057#, 0.0345* (total distance), 0.0001#, 0.0375##, 0.0338* (average speed) in graph N. (P) SNCA
pathology assessed by p129-α-syn immunoreactivity in TH + mDA neurons in the SN. Significantly different at P = 0.019* in graph P and P = 0.0001#, 0.0009##,
0.032* in graph Q and P = 5.1E-09#, 5.1E-09##, 0.0001* in graph R and P = 5.1E-09#, 5.1E-09##, 0.0005* in graph S and P = 5.1E-09#, 7.83E-09##, 0.0025* (TH),
0.0006#, 0.0062##, 0.041* (DAT) in graph U. n = 5 GSK-650394-treated SNCA-PD mice, 5 vehicle-treated SNCA-PD mice, and 8 SNCA-untreated non-PD mice.
Data information: Data are represented as mean  SEM. One-way ANOVA. Scale bar, 100 µm.
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effective disease-modifying therapies that rescue degenerating
neurons have not yet been developed. The idea of correcting
pathologic brain environments by targeting glial cells has been
appearing on the therapeutic horizon for CNS disorders (Hamby
& Sofroniew, 2010). This study provides an example for how to
develop an effective glial targeting strategy to treat neurodegener-
ative disorders, especially PD.
We initiated this study by identifying SGK1 as a molecule that is
downregulated at the transcriptional level by Nurr1 + Foxa2 and











Figure 8. Intra-SN injection of sh-Sgk1 AAV9 as another potential therapeutic strategy in PD.
A, B Efficiency of AAV9-mediated gene delivery. AAV9 viruses expressing the reporter GFP gene were stereotaxically injected into the SN of mice, and GFP expression in
astrocytes, microglia, and neuronal cells was quantified. Data are represented as mean  SEM. n = 3 mice (> 5 randomly selected microscopic fields per animal
were counted). Significantly different at P = 0.006*, 5.1E-09#, 5.36E-09+ in graph B.
C–O Therapeutic effects of intra-SN injection of sh-Sgk1 AAV9 in SNCA-PD mouse model. (C) Schematic of the experimental procedure. (D and E) SGK1 knockdown effect
in vivo by treatment with shSgk1-AAV9. Total SGK1 mRNA levels were estimated in the midbrain SN of the PD mice injected with shSgk1 (sh-Control as control)
AAV9 using real-time PCR (D). Cell type-specific SGK1 knockdown was estimated by counting SGK1-immuonoreactivity in neuron (MAP2+), astrocyte (GFAP+), and
microglia (Iba1+) populations (E). Data are represented as mean  SEM. n = 4 mice in each group. Significantly different at P = 0.0004# in graph D and
P = 0.049*, 0.007**, 0.002*** in graph E. (F–H) Behavior of the PD mice assessed by pole (F), beam (G) at 6–12 weeks, and locomotor activity (H) tests at 12 weeks
post-SNCA injection. Significantly different at P = 0.0003#, 0.0428*, 7.46E-06##, 0.0012** in graph F and P = 8.04E-08#, 0.004*, 1.62E-09##, 3.3E-06** in graph G
and P = 0.0002#, 0.0194* (total distance), 9.54E-06#, 0.0047* (average speed) in graph H. (I–O) Histologic assessment of p129-SNCA immunoreactivity (I, J), TH+
mDA neuron counts (I, K), neurite lengths (L), and cell body sizes (M) in the SN and TH+ and DA transporter (DAT) fiber intensities in the striatum (N, O).
Significantly different at P = 0.0001* in graph J, P = 2.35E-25#, 1.09E-16##, 4.36E-08* in graph K and P = 1.5E-40#, 1.08E-24##, 2.32E-07* in graph L and
P = 9.07E-20#, 2.59E-16##, 0.05* in graph M and P = 4.62E-22#, 5.11E-12##, 3.49E-06* (TH), 1.58E-22#, 8.13E-09##, 7.42E-09* in graph O. n = 7 sh-SGK1-AAV9-
treated PD mice, 7 sh-cont-AAV9-treated PD mice, and 8 SNCA-untreated mice. Data are represented as mean  SEM. One-way ANOVA. Scale bar, 100 µm.
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in glia. How Nurr1 + Foxa2 regulates SGK1 expression is intriguing
but has not been identified in this study. Nurr1 and Foxa2 have
naı̈ve roles as transcription factors that activate gene transcription.
Thus, Nurr1 + Foxa2-induced downregulation of SGK1 is likely
mediated in an indirect manner via activation of molecular tran-
scriptions or pathways that can inhibit SGK1 transcription. SGK1
transcription is controlled by a wide variety of stimuli including cell
stress, hormones, cytokines, cytosolic Ca2+ activity, and a number
of intracellular pathways. Specifically, oxidative stress and DNA
damage are common stimulators of SGK1 transcription (Leong et al,
2003; Lang et al, 2006), while Nurr1 and Foxa2 have been shown to
ameliorate those cellular stresses by promoting trophic and stress
responses, mitochondrial gene expressions, and DNA repair
function (Sousa et al, 2007; Song et al, 2009; Malewicz et al, 2011;
Kadkhodaei et al, 2013; Oh et al, 2015), implying that SGK1 expres-
sion was indirectly controlled by Nurr1 and Foxa2 actions to relieve
cellular stresses. In addition, Nurr1 has been shown to exert an
epigenetic repressor function by forming a repressor complex
containing corepressor element 1 silencing transcription factor
(CoREST) complex (Saijo et al, 2009). Thus, a Nurr1 (Foxa2)-medi-
ated action to directly inhibit SGK1 gene transcription could not be
excluded.
We found that gene knockdown and pharmacological inhibition
of SGK1 in glial cells potently suppressed glial inflammatory reac-
tions mediated by the NFκB, inflammasome, and STING intracellu-










Figure 9. The Sgk1 inhibitor treatment blunted microglial activation, NLRP3-inflammation, and cell senescence in the SNs of PD mice.
A–C Quantitative and morphometric analyses of microglia in the SN area of SNCA-PD mice. Shown in (A) are representative views of Iba1+ microglia neighboring TH+
mDA neurons in the SNs of PD mice treated with GSK-650394 and vehicle. Insets, enlarged views for the boxed areas. Data are represented as mean  SEM. n = 3
mice per group. Significantly different at P = 1.49E-11* in graph B and P = 0.000003* in graph C.
D, E The M1 marker CD16/32 expression in Iba1+ microglia. Data are represented as mean  SEM. n = 3 mice per group. Significantly different at P = 0.0016* in graph
E.
F, G mRNA expression of NLRP3-inflammasome components and pro-inflammatory cytokines in MPTP (F) and SNCA (G) PD mice injected with the SGK1 inhibitor or
vehicle (control). Each bar represents the mean  SEM of 3 PCR values from each animal, n = 3 mice per group. Significantly different at P = 0.0372*, 0.0173**,
0.0003*** in graph F and P = 0.002#, 0.0113##, 0.0053###, 0.0001#### in graph G.
H–J ASC expression in the SNs and SN microglia of SNCA-PD mice. n = 5 mice per group. Data are represented as mean  SEM. Significantly different at P = 1.91E-09*
in graph I and P = 0.0079* in graph J.
K, L β-gal-stained cell senescence in SNCA-PD mouse SN. Data are represented as mean  SEM. n = 5 mice per group. Significantly different at P = 0.0001*.
Data information: Student’s t-test. Scale bar, 100 µm.
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cell senescence were also relieved by SGK1 inhibition, whereas glial
capacity to cleanse glutamate toxicity was potentiated. Ultimately,
silencing and pharmacological inhibition of SGK1 potentiated the
neurotrophic roles of glia and rescued mDA neurons from degenera-
tion and α-synucleinopathy in multiple in vitro and in vivo PD
models. It is likely that the multifaceted therapeutic functions
promoted by SGK1 inhibition are linked together by multiple posi-
tive feedback regulatory loops: SGK1 inhibition in glial cells first
blocks the inflammatory pathways by inhibiting the intracellular
NFκB pathway, which blocks the NFκB-mediated expression of pro-
inflammatory cytokines and inflammasome components. At the
same time, downregulation of NFκB promotes glial GLT1 (SLC1A2)
expression (Fine et al, 1996; Su et al, 2003; Boycott et al, 2008; Jiang
et al, 2019) and activity to clear glutamate-mediated excitatory toxi-
city. Reduced glial secretion of pro-inflammatory cytokines (TNFα)
could decrease intracellular oxidative and mitochondrial stress
(Blaser et al, 2016) in neighboring glia. Cell senescence in the glia is
thus ameliorated by the lowered ROS levels. At the same time, the
inflammasome and STING pathways are deactivated in the glia
treated with the SGK1 inhibitors and sh-Sgk1, not only by downreg-
ulated expression of the key components of the pathways, but also
by relief from mitochondrial stress, which is closely linked with the
activation of those pathways (Sorbara & Girardin, 2011; Heid et al,
2013; Liu et al, 2016; Panicker et al, 2019). On the other hand,
oxidative and mitochondrial stress in neuronal cells are also
relieved in the same manner by glia treated with SGK1 inhibition,
and another positive feedback regulation could also be established
among oxidative and mitochondrial stress and abnormal SNCA
aggregation: lowered ROS and mitochondrial dysfunction could
reduce SNCA aggregate formation and propagation (Lee, 2003;
Esteves et al, 2009; Esteves et al, 2011; Li et al, 2011; Scudamore &
Ciossek, 2018). Reciprocally, with relief from α-synucleinopathy,
mitochondria become healthier and more functional, and intra-
neuronal ROS is reduced (Hsu et al, 2000; Hashimoto et al, 2003;
Musgrove et al, 2019). The therapeutic effects attained by glial
SGK1 inhibition are summarized in Appendix Fig S9.
In addition to the knockdown strategy using sh-RNA delivery,
systemic administration of the SGK1 inhibitor GSK-650394 has
been demonstrated in this study as a potential therapeutic tool to
treat PD. Detectable levels of the inhibitor were found in the
brains of PD mice, suggesting that the therapeutic effects seen in
the PD mice after systemic injection of the SGK1 inhibitor
occurred because the inhibitor permeated into the brain and acted
on the glia there. However, the inhibitor concentration detected
in the brains of PD mice after i.p. injection (10.4  1.0 ng/g
brain) was low compared with the plasma concentration
(342.3  146.3 ng/ml), resulting in a brain to plasma concentra-
tion ratio of 0.03. More extensive optimization studies are
required to generate more efficient SGK1 inhibitor derivatives to
improve the brain pharmacokinetics in vivo. On the other hand,
PD is regarded as an auto-immune disease, with evidence for the
infiltration of peripheral T lymphocytes in postmortem brain
tissues of PD patients and alterations in T-cell subsets in the
blood of PD patients (Bas et al, 2001; Baba et al, 2005; Brochard
et al, 2009; Sie et al, 2014; Fahmy et al, 2019). Specifically,
recent experimental evidence has shown the pathologic roles of
helper T17 (Th17) lymphocytes in PD (Sommer et al, 2019),
whereas the adoptive transfer of regulatory T (Treg) cells has
manifested neuroprotective functions in an MPTP murine model
of PD (Reynolds et al, 2007), and altered Treg cells have shown
suppressive functions in PD patients (Saunders et al, 2012).
Notably, SGK1 has been shown to promote the activation and dif-
ferentiation of Th17 lymphocytes at the expense of those of Treg
cells (Du et al, 2018; Spagnuolo et al, 2018; Wu et al, 2018).
Thus, portions of the therapeutic effects seen following the
systemic administration of the SGK1 inhibitor could be mediated
through the correction of the Th17/Treg cell imbalance in the PD
animals. Studies are needed to address and identify the therapeu-
tic effects of SGK1 inhibition attained through T-cell modulation
in PD models.
In conclusion, our results provide evidence that SGK1 inhibition
in astrocytes and microglia can be therapeutically used in PD.
Because the glial pathologies shown to be improved by SGK1 inhibi-
tion in this study commonly underlie other CNS disorders, SGK1
inhibition might eventually become a therapeutic intervention that
is broadly applicable to a variety of neurodegenerative disorders
and neurologic injuries.
Materials and Methods
Cell cultures and treatments
Primary mixed glial culture
Mixed glia were isolated from mouse or rat VMs on postnatal day 1
(P1)–P5, using a previously described protocol (Oh et al, 2015). In
brief, VMs were removed, triturated in DMEM (Thermo Scientific
Inc., Waltham, MA, USA) containing 10% FBS (HyClone, GE Health-
care Life Sciences, Pittsburgh, PA, USA), and plated in 75-cm2 T-
flasks. When cell confluence reached 80–90%, cells were harvested
with 0.125% trypsin and sub-cultured on a culture surface coated
with poly-d-lysine (Millipore Sigma, Louis, MO, USA).
Primary astrocyte and microglial culture
Microglia and astrocytes were isolated from mixed primary glial
cultures obtained from the VMs of a P3 mouse or rat. Briefly, VMs
were dissected in Ca2+- and Mg2+-free HBSS (Thermo Scientific Inc.)
and incubated in a 0.125% trypsin solution for 10 min at 37 °C. The
resulting cell suspensions were diluted in complete medium
(DMEM-F12, Thermo Scientific Inc.) with 10% FBS, 10% horse
serum (HyClone), 1 mM L-glutamine (Life Technologies, Carlsbad,
CA, USA), and 1% PenStrep (Thermo Scientific Inc.) and cultured
for 14 days. Floating microglia and attached pure astrocytes were
collected from the mixed glial cultures by shaking the flask on an
orbital shaker at 0.4 g for 12 h at 37°C.
Cultures enriched with mDA neurons
Neural stem/precursor cells cultured from VM in the early embry-
onic days have mDA neurogenic potential without glial differentia-
tion (Studer et al, 1998). Therefore, mDA neuron-enriched cultures
were attained by differentiating NSCs cultured from the VMs of
mouse (ICR) embryos at E10.5 or VMs of rat (Sprague Dawley)
embryos at E12, as previously described (Song et al, 2018). In addi-
tion, mDA neurons were directly isolated and cultured from rat VMs
by adopting the method for conventional primary neuron culture
(Kaech & Banker, 2006). Briefly, VM tissues from rats at E14–16
18 of 26 EMBO Molecular Medicine 13: e13076 | 2021 ª 2021 The Authors
EMBO Molecular Medicine Oh-Chan Kwon et al
were triturated to single cells with papain (Sigma) and plated on
culture dishes pre-coated with polyornithine (PLO)/fibronectin (FN)
in neurobasal medium supplemented with B27 and L-glutamine (all
from Thermo Scientific Inc.). Glial cell populations were eliminated
by adding Ara-C (3 µM; Sigma) for days 3–5.
mDA neuron-VM-glia co-culture
The differentiated VM-NSC culture (mDA neuron-enriched culture)
was harvested and mixed with primary culture for VM-glia in the
ratio 2:1 and then cultured. For analyses, the cells were treated with
SGK1 inhibitors [GSK650394 (1–2 μM) (Tocris Bioscience, Bristol,
U. K.) or EMD638683 (1–2 μM) (Chemscene, Monmouth Junction,
NJ, USA)] with or without toxins, LPS (0.25 µg/ml, Sigma), H2O2
(150–500 µM, Sigma), ATP (2.5 mM, Sigma), or Paraquat (50 µM,
Sigma). The specificity of the SGK1 inhibitors has been shown with
low levels of cross-reactivity with other members of the AGC Ser/
Thr protein kinase family such as AKT or PDK1(Sherk et al, 2008;
Ackermann et al, 2011).
In vitro overexpression of Nurr1, Foxa2, SGK, and knockdown
of SGK1
Lentiviral vectors expressing Nurr1 (mouse), Foxa2 (rat), and SGK1
(mouse), all from mouse genes under the control of the CMV
promoter, were generated by inserting the respective cDNA into the
multi-cloning site of pCDH (System Biosciences, Mountain View,
CA, USA). The lentiviral vector pGIPZ-shSGK1 was purchased from
Open Biosystems (Huntsville, AL, USA). The empty backbone
vector (pCDH or pGIPZ) was used as the negative control. Titers of
the lentiviruses were determined using a QuickTiter HIV Lentivirus
Quantitation Kit (Cell Biolabs, San Diego, CA, USA), and 20 µl each
of the viruses with 1.0 × 106 transducing units (TU)/ml were mixed
with 2 ml of medium and added to 1–1.5 × 106 cells/6 cm-dish for
the transduction reaction. For siRNA-mediated SGK1 knockdown,
VM-glia were transfected with siRNA targeting mouse SGK1
(GCTATCTGCACTCCCTAAACA) or control siRNA (scrambled
sequence) using Lipofectamine 2000 and 3000 reagents (Thermo
Scientific Inc.) according to manufacturer’s instructions.
CM preparation and treatment
Fresh N2 medium or HBSS was added to VM-glial cultures (trans-
duced with sh-Sgk1 or sh-cont), and the GCM was collected every
other day for 6 days. The GCMs were adjusted to 0.1–0.15 mg of
protein/ml, filtered at 0.45 μm, and stored at − 80°C until use. The
GCMs were diluted with N2 medium (1:1, v/v) before adding to the
cells in culture.
RNA-sequencing analysis
RNA-sequencing was carried out at E-biogen (Seoul, Korea). After
trimming the reads with a 9 quality score of less than 20 using
FastQC and checking the mismatch ratio using Bowtie, all RNA-seq
data were mapped to the mouse reference genome (GRCm38/
mm10) using STAR. To measure the expression levels of all 46,432
annotated genes, 107,631 transcripts, and 1,276,131 protein-coding
(mRNA) records in the mouse genome (based on NCBI RefSeq 13
annotations Release 105: February 2015), we counted reads mapped
to the exons of genes using Htseq-count and calculated the frag-
ments per kilobase of exon per million fragments (FPKM) value.
Gene classification was based on searches submitted to DAVID
(http://david.abcc.ncifcrf.gov/). Gene ontology (GO) and KEGG
pathway analyses were performed using DAVID Bioinformatics
Resources version 6.8. Heatmap data were generated by MeV 4.9.0.
Scatterplot (EXDEGA_v1.6.7, E-biogen) and GSEA (GSEA 4.0.0,
Broad Institute, Cambridge, MA, USA) clustering software were
used for further analyses.
Immunostaining
Cultured cells were fixed with 4% paraformaldehyde in PBS,
blocked in 0.3–0.6% Triton X-100 with 1% bovine serum albumin
for 40–60 minutes, and then incubated with primary antibodies
overnight at 4°C. Primary antibody information is shown in
Appendix Table S2. Secondary antibodies tagged with Cy3 (1:200,
Jackson Immunoresearch Laboratories, West Grove, PA, USA) or
Alexa Fluor 488 (1:200, Life Technologies) were used for visualiza-
tion. The stained cells were mounted using VECTASHIELD with
DAPI mounting solution (Vector Laboratories, Burlingame, CA), and
images were obtained with an epifluorescence microscope (Leica,
Heidelberg, Germany) and confocal microscope (Leica PCS SP5).
To analyze cell maturation, total fiber length, soma size, and
intensity, the cells were measured using an image analysis system
(Leica LAS).
Western blotting
Protein was extracted using a RIPA buffer containing a protease
inhibitor (Roche, Mannheim, Germany). For cytosolic and nuclear
fractionation, cells were prepared using an EpiQuik kit (Epigentek,
Brooklyn, NY, USA). Proteins were electrophoresed on SDS–PAGE
gel (12% or 4–16% for SNCA aggregate detection), transferred to a
nitrocellulose (or polyvinylidene fluoride) membrane, blocked, and
then incubated with the primary antibodies listed in
Appendix Table S2. Signals were visualized with horseradish perox-
idase-conjugated antibodies and captured with ChemiDoc (Bio-Rad,
Hercules, CA, USA).
Densitometric quantification of the bands was performed using
ImageJ (Image Processing and Analysis in Java, NIH).
Real-time PCR
Total RNA was prepared using the Trizol reagent (Invitrogen, Carls-
bad, CA, USA) through the RNA isolation protocol. cDNA synthesis
was carried out using a Superscript kit (Invitrogen). Real-time PCR
was performed on a CFX96TM Real-Time System using iQTM SYBR
green supermix (Bio-Rad, Hercules, CA, USA), and gene expression
levels were determined relative to GAPDH levels.
See Appendix Table S1 for a list of the primers.
ELISA for IL-1β and IL-6
Cultured cell supernatants were diluted (1:40) and assayed for IL-1β
and I-L6 protein levels using enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions.
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Mitochondrial assays
Mitochondrial protein dynamics were determined using the inte-
grated portions of young (green) and old (red) MitoTimer proteins
(Hernandez et al, 2013). Briefly, cells were transduced with the
lentiviruses expressing the pMitoTimer vector (Addgene52659;
Addgene, Watertown, MA, USA), and 3–4 days later, the ratio of red
to green fluorescence intensities was quantified. Mitochondrial ROS
was estimated using MitoSox (Thermo Scientific Inc) and following
the manufacturer’s protocols. Mitochondrial membrane potential
was estimated with a NucleoCounter3000 (NC3000; ChemoMetec,
Allerod, Denmark). Intracellular ATP content was measured using
an ATP determination kit (Molecular Probes, Eugene, OR, USA).
Oxidative stress, cell senescence, and viability
Intracellular ROS levels were determined by staining with the ROS
indicator 5-(and-6)-chloromethyl-20,70-dichlorodihydrofluorescein
diacetate [CM-H2DCF-DA, DCF) (Life Technologies)]. Cell senes-
cence was assessed using an SA-β-gal staining kit (Abcam,
Cambridge, UK). In certain cases, the senolytic drugs fisetin and
azithromycin were used. Cell viability was assessed with a CCK8 kit
(D-Plus™, DonginBio, Seoul, Korea).
Analyses for SNCA propagation
Purification of recombinant SNCA and SNCA PFFs
Recombinant SNCA and SNCA fibrils were prepared as described
previously (Choi et al, 2015). Briefly, 5 mg/ml monomeric SNCA
was incubated at 37°C with continuous agitation at 250 rpm for
2 weeks, sonicated on ice for 3–5 s, and stored at − 80°C until use
as SNCA fibrils. The status of SNCA fibrils was determined using
the thioflavin T binding assay and an electron microscopic observa-
tion per preparation.
SNCA aggregation analysis
The levels of SNCA aggregate formation were detected in differenti-
ated VM-NPC cultures overexpressing SNCA or treated with SNCA
PFFs (1 µg/ml of medium). For SNCA overexpression, VM-NPCs
were transduced with lentiviruses expressing human SNCA (pEF1α-
α-syn) and differentiated for 15 days. The SNCA oligomers and fib-
rils were detected with immunocytochemical (p129-SNCA, BioLe-
gend, San Diego, CA, USA) and Western blot (SNCA, BD
Biosciences, San Jose, CA, USA) analyses on 20–7% gradient SDS–-
PAGE, as described above. The levels of SNCA aggregation were also
estimated using immunocytochemical analysis for the Bi-FC assay.
The VM-NSCs were co-transduced with lentiviruses expressing
Venus1-α-syn (V1S; N-terminal of SNCA) and α-syn-Venus2 (SV2; C-
terminal of SNCA) and differentiated into mDA neurons for 15 days.
Bi-FC-SNCA aggregates were quantified by counting GFP+ puncta.
Glutamate uptake
Cells were washed twice in tissue buffer (5 mM Tris, 320 mM
sucrose, pH 7.4) and exposed to 10 µM glutamate in either Na+-
containing Krebs buffer (120 mM NaCl, 25 mM NaHCO3, 5 mM KCl,
2 mM CaCl2, 1 mM KH2PO4, 1 mM MgSO4, and 10% glucose) or
Na+-free Krebs (120 mM choline-Cl and 25 mM Tris–HCl) for
10 min at 37°C. Uptake was stopped by placing the cells on ice and
washing them twice with wash buffer (5 mM Tris/160 mM NaCl,
pH 7.4). Cells were collected and homogenized in 100 µl of assay
buffer, and the amount of glutamate in the cell homogenates was
measured using a glutamate assay kit (Abcam, Cambridge, MA,
USA). Na+-dependent uptake was determined by subtracting Na+-
free counts from the total counts in the presence of Na+.
Determination of intracellular GSH levels
Intra-neuronal GSH levels were determined as previously described
(Jeong et al, 2019). Cells were incubated for 2 h with FreSHtracer™
(2 μM, Cell2in, Seoul, Korea), which binds to GSH and emanates
fluorescence at 510 nm (peak fluorescence of free form at 580 nm).
After washing with D-PBS, fluorescence readings were taken at
580 nm and 510 nm using an Arial II flow cytometer (BD Bios-
ciences, Franklin Lakes, NJ, USA). The GSH levels are expressed as
the ratio of the fluorescence at 510 and 580 nm.
Assay of NLRP3 inflammasome
To induce conventional NLRP3 inflammasome activation, cells were
primed with LPS (0.25 − 1 μg/ml, 3 h), followed by ATP treatment
(2–2.5 mM, 30–45 min). Inflammasome activation was determined
by the presence of active caspase-1 (p10) and active IL-1β in immu-
noblots from the culture supernatant and by extracellular IL-1β
quantification using ELISA (Lee et al, 2019).
Animal housing
All procedures for animal experiments were approved by the Institu-
tional Animal Care and Use Committee at Hanyang College of Medi-
cine under approval number 2018-0217A. Mice were housed in a
specific pathogen-free barrier facility with a 12-h light/dark cycle
and maintained on standard chow (5053 PicoLabR Rodent Diet 20).
Experiments were performed in accordance with NIH guidelines.
Preparation of PD mouse models
To generate PD mice by MPTP injection, female ICR mice (10–-
14 weeks old) received i.p. injections of MPTP (30 mg/kg) once
daily for five consecutive days (Jackson-Lewis & Przedborski,
2007). SNCA-induced PD mice were generated by combined treat-
ment with AAV2 expressing human SNCA (α-syn-AAV2) and SNCA
PFFs (Thakur et al, 2017). To this end, female mice were anes-
thetized by Zoletil50 (0.1 mg/kg) mixed with Rompun (93.28–l g/
kg), and SNCA PFF (2 µl, 5 mg/ml in PBS) and α-syn-AAV2 (2 µl,
2.1 × 1012 GC/ml) were injected bilaterally into the SN (3.3 mm
posterior to bregma;  1.2 mm lateral to midline;-4.6 mm ventral to
dura) (the same volume of PBS injected for control). The infusion
was performed at a rate of 0.25 μl per min. The needle (26 gauge)
was left in the injection site for 25–30 min after completion of each
injection and then removed slowly.
In vivo SGK1 inhibition in PD model mice
The SGK1 inhibitor GSK-650394 was administered (3 mg/kg, i.p.,
once a day) beginning a week after SNCA or the last MPTP
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injection. In other cases, AAV9 expressing sh-Sgk1 (sh-Sgk1-
AAV9) or Sh-control-AAV9 (control) was stereotaxically injected
into the SNs of the PD mice one week after the combined SNCA
treatment.
AAV production
AAV9 and 2 expressing sh-SGK1 or SNCA, respectively, under the
control of the CMV promoter were generated by subcloning the
respective cDNAs into the pAAV-MCS vector (Addgene). Packaging
and production of the AAVs (serotypes 2 and 9) was completed by
KIST Virus Core (Seoul, Korea). AAV titers were determined with a
QuickTiterTM AAV Quantitation Kit (Cell Biolabs).
Behavior tests
Pole test
Animals were placed head upwards on top of a vertical wooden
pole 50 cm in length (diameter, 1 cm). The base of the pole was
placed in the home cage. Once placed on the pole, animals
oriented themselves downward and descended the length of the
pole back into their home cage. All of the animals received 2 days
of training that consisted of five trials for each session. On the test
day, animals received five trials, and the time to orient downward
was measured.
Challenging beam traversal test
Motor performance was measured with a novel beam test adapted
from traditional beam-walking tests. Briefly, the beam (length, 1 m)
started at a width of 3.5 cm and gradually narrowed to 0.5 cm in 1-
cm increments. Animals were trained to traverse the length of the
beam, starting at the widest section and ending at the narrowest
section, for 2 days before real testing. The time required for each
animal to traverse the beam was measured.
Locomotion test
The locomotor activities of the PD mice were monitored using a
camera (HD C310, Logitech, Switzerland). Briefly, mice were placed
in the center of a 40-cm square cage and allowed to freely explore
the apparatus for 20 min while being tracked by a video-recording
system. After each test, each mouse was returned to its home cage,
and the open field was cleaned with 70% ethyl alcohol and permit-
ted to dry. To assess the process of habituation to the novelty of the
arena, mice were exposed to the apparatus for 20 min on two
consecutive days for statistical analysis. Total distance and average
speed were measured automatically by the software (Stoelting Co.,
IL, USA).
Histological analysis
Mice were anesthetized as described above. Brains were sliced at
a thickness of 1 mm on a mouse brain slice matrix (ZIVIC Instru-
ments), and 4–6 regions of the SN (ca 1 × 2 mm) were dissected
and subjected to real-time PCR analysis. For immunohistochem-
istry, mice were perfused intracardially with 4% paraformalde-
hyde in PBS. Brains were removed and immersed in 30% sucrose
in PBS until they sank. Midbrain and striatal regions were sliced
into 30 µm thicknesses on a freezing microtome (CM 1850; Leica,
Wetzlar, Germany) and subjected to immunofluorescence staining.
TH+ mDA neurons in the SN were counted every 8 sections
throughout the midbrain, and total SN mDA neuron numbers
were calculated. TH+ fiber lengths, the soma sizes of mDA
neurons and microglia in the SN, and TH + fiber intensities in
the striatum were measured using an image analysis system
(Leica LAS).
Determination of the level of the SGK1 inhibitor GSK-650394 in
the brains of PD mice
The level of the SGK1 inhibitor GSK-650394 in the brains of PD mice
was determined according to a previous report (Ham et al, 2019).
Briefly, the brain tissues were collected 30 min after the last admin-
istration of GSK-650394 at a dose of 3 mg/kg. Residual blood
contamination was removed by intracardial perfusion with saline.
The collected mouse brains were quickly washed with ice cold
saline three times and further homogenized in a two-fold volume of
PBS on ice. Then, 50 μl of brain homogenate or plasma was depro-
teinized by adding 100 μl of methanolic solution containing the
internal standard (IS) ondansetron. After centrifugation at
14,000 rpm for 15 min at 4°C, the supernatant was injected into the
LC-MS/MS system, an Agilent HPLC system (1290 Infinity, Agilent
Technologies, Santa Clara, CA) and Agilent 6490 QQQ mass spec-
trometer with a positive electrospray ionization (ESI+) Agilent Jet
Stream ion source (Agilent Technologies, Santa Clara, CA). A good
separation of the SGK1 inhibitor and IS from endogenous
The paper explained
Problem
Neuronal cells have been the central cell type targeted for drug devel-
opment in CNS disorders. However, effective disease-modifying thera-
pies that rescue degenerating neurons have not yet been developed.
It is mainly because astrocytes and microglia, brain-resident glia,
establish harmful inflammatory environments in disease contexts and
thereby contribute to the progression of neuronal loss in neurodegen-
erative disorders. Correcting the diseased properties of glia is therefore
an appealing strategy for treating brain diseases.
Results
In this study, we show that inhibiting glial SGK1 corrects the pro-in-
flammatory properties of glia by suppressing the intracellular NFκB-,
NLRP3-inflammasome, and CGAS-STING-mediated inflammatory path-
ways. Furthermore, SGK1 inhibition potentiated glial activity to scav-
enge glutamate toxicity and prevented glial cell senescence and
mitochondrial damage. Along with those anti-inflammatory/neu-
rotrophic functions, silencing and pharmacological inhibition of SGK1
protected midbrain dopamine neurons from degeneration and cured
pathologic synuclein alpha (SNCA) aggregation and Parkinson disease
(PD)-associated behavioral deficits in multiple in vitro and in vivo PD
models.
Impact
Our results provide evidence that SGK1 inhibition in astrocytes and
microglia can be therapeutically used in PD. Because the glial
pathologies shown to be improved by SGK1 inhibition in this study
commonly underlie other CNS disorders, SGK1 inhibition might even-
tually become a therapeutic intervention that is broadly applicable to
a variety of neurodegenerative disorders and neurologic injuries.
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substances was achieved using a Synergi 4 μm polar-RP 80A
column (150 mm × 2.0 mm, 4 μm, Phenomenex, Torrance, CA).
The mobile phase was a mixture of 0.1% formic acid and acetoni-
trile (20:80) at a flow rate of 0.2 ml/min. The injection volume was
2 μl. For multiple reaction monitoring in the ESI+ mode, the transi-
tion of m/z 383.1 → 314.9 and m/z 294.1 → 170 was applied for
the SGK1 inhibitor and IS, respectively. The linearity was good, with
a weighing of 1/x over the calibration range (5–10,000 ng/ml,
R > 0.9944). The observed concentration in the brain is expressed
as ng/g of brain.
Statistical analysis
Animal behavioral assays in this study have been assessed by an
independent experimenter blinded to treatment condition. In culture
wells (coverslips) and brain sections, immunostained and DAPI-
stained cells were counted in 5–20 random areas using an eyepiece
grid at a magnification of 200× or 400×, and total positive cells (or
percentages) in a well were calculated. All data are expressed as the
mean  SEM, and statistical tests are justified as appropriate. Statis-
tical comparisons were made using the Student’s t-test (unpaired) or
one-way analysis of variance (ANOVA) followed by Bonferroni post
hoc analysis using SPSS (Statistics 21; IBM Inc. Bentonville, AR).
The n, P-values, and statistical analysis methods are indicated in the
figure legends.
Data availability
The datasets produced in this study are available in the following
databases: RNA-seq data: Gene Expression Omnibus: GSE106216
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE106216).
Microarray data: NCBI GEO: GSE145489 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE145489).
Expanded View for this article is available online.
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